The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...

Americans are running out of time to claim a $1,400 stimulus check. Tuesday marks Tax Day as well as the three-year deadline ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity is now under attack on multiple fronts, from ...

The Trump administration has decided not to go forward with a proposal for Medicare and Medicaid to cover high-demand obesity ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 billion) in Brazil to increase production at its facility in Minas Gerais.

SAO PAULO (Reuters) - Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil to boost production, it said on Monday. The ...

SAO PAULO, April 7 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil to boost ...

Bangkok, April 2025 – Chulalongkorn University, in collaboration with Novo Nordisk Pharma (Thailand) Ltd., has officially launched “Chulalongkorn x Novo Nordisk: Enhancing Obesity Management ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage of anti-obesity drugsThe Trump administration says it will ...